Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. November 2011 09:17 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Name Change and Corporate Restructuring

VANCOUVER, British Columbia and PHOENIX, Nov. 8, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual and orodispersable drugs...
15. September 2011 13:07 ET | Quelle: Global Health Ventures Inc.

Better Investing National Convention to Host Global Health Ventures Inc. CEO to Present GHLV Sublingual Drug Delivery System September 17th, 2011

VANCOUVER, British Columbia, Sept. 15, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to...
23. August 2011 09:22 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Inc. CEO's Exclusive Interview With PremierStocks.tv at The MoneyShow in San Francisco, CA of Sublingual Drug Delivery System

PHOENIX, Ariz. and VANCOUVER, B.C., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with a focus on sublingual drug delivery, is pleased...
12. Juli 2011 09:14 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Initiates Development of Sublingual NSAIDs

VANCOUVER, British Columbia, July 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to...
06. Juli 2011 09:19 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Appoints New Senior Vice President and Chief Operating Officer

VANCOUVER, British Columbia, July 6, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery, is pleased to...
22. Juni 2011 09:17 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Completes European Clinical Trials Phase I for X-Excite vs. Viagra(R)

VANCOUVER, British Columbia, June 22, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to...
02. Juni 2011 09:12 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Engages FDA Approved Contract Manufacturing Company for the Production of X-Excite

VANCOUVER, British Columbia, June 2, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce...
27. April 2011 08:56 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures to Initiate Discussion With Omnicare on X-Excite vs. Viagra(R) Trials in the United States

VANCOUVER, British Columbia, April 27, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce that it has started discussions for...
12. April 2011 08:56 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Completes X-Excite Formulation for North American Clinical Trials

VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) a specialty pharmaceutical company is pleased to announce that has completed the final...
30. März 2011 09:12 ET | Quelle: Global Health Ventures Inc.

Global Health Ventures Announces Interim Data From the European Clinical Trails of X-Excite vs. Viagra

VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company, is pleased to announce the interim results of the clinical...

Nächste Seite